Table 1.

Select clinical trials of temsirolimus (CCI-779) in glioblastoma.

Study (year)	Phase	Dose (n)	PR (%)	OS	PFS	Ref.
Chang et al. (2005)	II	170 mg/week iv. (n = 16); 250 mg/week iv. (n = 27)	4.9	Median: N/A; 6-month: N/A	Median: 9 weeks; 6-month: 2.4%	[16]
Galanis et al. (2005)	II	250 mg/week iv. (n = 65)	0	Median: 4.4 months; 6-month: 7.8%	Median: 2.3 months; 6-month: 7.8%	[17]
Lassen et al. (2013)	II	25 mg/week iv. (n = 13)	0	Median: 15 weeks; 6-month: N/A	Median: 8 weeks; 6-month: N/A	[23]
Lee et al. (2012)	I/II	25 mg/week iv. (n = 18)	11.7	Median: N /A; 6-month: N/A	Median: 8 weeks; 6-month: 0%	[24]

iv.: Intravenous; N/A: Not assessed; OS: Overall survival; PFS: Progression-free survival; PR: Partial response.